Results 281 to 290 of about 101,548 (353)

Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis

British Journal of Pharmacology, Volume 183, Issue 5, Page 1030-1047, March 2026.
Background and Purpose Myocardial fibrosis (MF), a hallmark of structural cardiac remodelling, drives disease progression across most forms of heart failure and plays a central role in heart failure with preserved ejection fraction (HFpEF). Despite its clinical relevance, effective treatments remain scarce.
Sheyla Barrado‐Ballestero, Sarah Torp Yttergren, Max Hahn, Marie Biviano Rosenkilde, Ditte Marie Jensen, Michael Christensen, Louise Thisted, Heidi Lindgreen Holmberg, Geoffrey Teixeira, Tor Biering‐Sørensen, Casper Gravesen Salinas, Urmas Roostalu   +11 more
wiley   +1 more source

Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. [PDF]

Front Nutr
Johnson B, Milstead M, Thomas O, McGlasson T, Green L, Kreider R, Jones R.   +6 more
europepmc   +1 more source

Efficacy and safety of CT‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1673-1682, March 2026.
Abstract Aims To assess the glycaemic efficacy and safety of CT‐868, a cAMP signal‐biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in participants with type 2 diabetes (T2D). Materials and Methods This 26‐week (W), phase 2, randomized, double‐blind placebo‐controlled trial enrolled adults with T2D ...
Manu V. Chakravarthy, Michael A. Elliott, Luis Acosta, Gabriele E. Sonnenberg, Damian Bialonczyk, Jingtao Wu, Federico A. Argüelles‐Tello, Raymundo Garcia‐Reza, José Gerardo González‐González, Stig K. Hansen, Juan P. Frias   +10 more
wiley   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonist Exposure on Gastrointestinal Outcomes Among ICU Patients: A Multicenter Matched Cohort Study. [PDF]

Crit Care Explor
Gmehlin CG, Nemet M, Rizwan ZM, Ahmad S, Gajic O, Tekin A.   +5 more
europepmc   +1 more source

Burden of long‐term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT‐O study

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1683-1692, March 2026.
Abstract Aims The multi‐country epIdeMiology landscape PAtient Care paThways of Obesity (IMPACT‐O) retrospective cohort study utilised existing electronic medical records to gather data on overweight and obesity. We report UK data on obesity‐related complications (ORCs) and management strategies.
Kamlesh Khunti, Matt Capehorn, Esther Artime, Lill‐Brith von Arx, Alun L. Davies, Atif Adam, Anastasia Lampropoulou   +6 more
wiley   +1 more source

Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes. [PDF]

Ann Surg
Aschen SZ, Zhang A, O'Connell GM, Salingaros S, Andy C, Rohde CH, Spector JA.   +6 more
europepmc   +1 more source

Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma. [PDF]

World J Gastroenterol
Trakoonsenathong R, Chiu CF, Saengboonmee C.   +2 more
europepmc   +1 more source

Endoscopy and anesthesia outcomes associated with glucagon-like peptide-1 receptor agonist use in patients undergoing outpatient upper endoscopy. [PDF]

Gastrointest Endosc
Panchal S, Mahmud N, Atkins JH, Kang H, Leto A, Goebel A, Trivedi N, Chatila A, Hsu WW, Ginsberg GG, Pickett-Blakeley O, Zandvakili I.   +11 more
europepmc   +1 more source

Semaglutide versus caloric restriction‐induced weight loss: insights into effects on skeletal muscle mass and function

The Journal of Physiology, EarlyView.
Harsh Shah, Julio E. Ayala
wiley   +1 more source

Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist. [PDF]

Diabetes Obes Metab
Horváth L, Novodvorský P, Haluzík M.
europepmc   +1 more source